# TOFACITINIB CITRATE by Stellon Biotech Inc.: new human prescription drug listing

**Launch Signal Score:** 65/100

| Field | Value |
|---|---|
| Product | TOFACITINIB CITRATE |
| Generic name | TOFACITINIB CITRATE |
| NDC | 85972-122 |
| Labeler | Stellon Biotech Inc. |
| Product type | HUMAN PRESCRIPTION DRUG |
| Approval pathway | ANDA |
| Application number | ANDA218821 |
| Dosage form | TABLET, FILM COATED |
| Route | ORAL |
| Active ingredients | TOFACITINIB CITRATE 16.16 mg/1 |
| Marketing start | 2026-10-01 |
| Package configurations | 1 |

## Why this score
- Prescription or biologic product.
- New generic entry: wholesalers and GPOs re-bid contracts.

Source: U.S. FDA National Drug Code (NDC) Directory via openFDA (https://dailymed.nlm.nih.gov/dailymed/search.cfm?labeltype=all&query=85972-122). Last refreshed: 2026-11-03T18:09:00.764Z.
Listing data comes from the FDA NDC directory via openFDA; a listing is not an FDA approval or endorsement and may be updated or withdrawn. Informational only; not medical advice.